CRBP — Corbus Pharmaceuticals Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1595097 ·
Last close
$5.38
Market Cap
$104.06M
52W High
$20.56
52W Low
$5.13
ADV30
1,192,634
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -36,190,000 | -35,037,000 | 126,988,000 | 23,370,000 | 24,748,000 |
| Mar 2026 | 0 | — | -24,304,000 | -22,969,000 | 144,480,000 | 25,661,000 | 18,138,000 |
| Dec 2025 | 0 | — | -21,966,000 | -20,555,000 | 168,195,000 | 28,492,000 | 20,692,000 |
| Sep 2025 | 0 | — | -24,417,000 | -23,342,000 | 109,514,000 | 26,983,000 | 17,367,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-86,668,000
Investing CF
$3,208,000
Financing CF
$77,426,000
CapEx
$-12,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.19
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-613,436,000
Inventory
—
Receivables
—
ST Investments
$94,571,000
EBIT TTM
$-104,391,000
Pretax Income TTM
$-101,903,000
Interest Exp TTM
$0
Analysts
10
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -85,310,000 | -78,537,000 | 168,195,000 | 20,692,000 | 147,503,000 | -64,491,000 |
| Dec 2024 | 0 | -48,721,000 | -40,209,000 | 155,879,000 | 13,451,000 | 142,428,000 | -41,794,000 |
| Dec 2023 | 0 | -45,078,000 | -44,604,000 | 28,272,000 | 35,177,000 | -6,905,000 | -36,100,000 |
| Dec 2022 | 0 | -34,835,445 | -42,346,903 | 66,311,940 | 33,321,923 | 32,990,017 | -37,544,435 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-84,528,000
OpCashFlow TTM
—
Assets (Latest)
$144,480,000
Forward EPS
$-5.51
Max Pain — expiry 2026-12-18
max pain strike: $7.50 · spot: $5.38 · call oi: 3,839 · put oi: 10,256
Expected Move to 2026-12-18:
±$2.90
(53.90%) —
implied range
$2.48 –
$8.28
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AARD | Aardvark Therapeutics, Inc. | $104.17M | $4.76 | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $105.33M | $7.03 | — |
| BMEA | Biomea Fusion, Inc. | $102.67M | $1.42 | — |
| KZIA | KAZIA THERAPEUTICS LTD | $102.04M | $8.93 | — |
| ANIX | Anixa Biosciences Inc | $100.82M | $2.90 | — |
News headlines (Yahoo Finance, 1h cache)
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
2026-09-29 12:00 · Yahoo
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
2026-09-15 08:02 · Yahoo
Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data
2026-09-14 13:28 · Yahoo
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
2026-09-14 11:00 · Yahoo
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
2026-09-11 20:01 · Yahoo
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
2026-08-06 12:00 · Yahoo
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
2026-07-28 12:00 · Yahoo
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
2026-06-01 14:04 · Yahoo
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
2026-05-21 12:00 · Yahoo
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-13 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.